Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Pediatría | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension
INTERVENTIONAL
Inicio: 1 de may de 2005
ID: NCT00151775
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Placebo-controlled, Double-blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Severe Alopecia Areata
INTERVENTIONAL
Inicio: 11 de oct de 2023
ID: NCT06012240
Activo, no recluta
ClinicalTrials.gov
PROSpect: Prone and Oscillation Pediatric Clinical Trial
INTERVENTIONAL
Inicio: 1 de may de 2019
ID: NCT03896763
Reclutando
Fase 4
ClinicalTrials.gov
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment
INTERVENTIONAL
Inicio: 30 de ago de 2022
ID: NCT04877522
Reclutando
ClinicalTrials.gov
Trauma-informed Obstetric Care for Perinatal Health in Women With Histories of Childhood Abuse: a Pilot Randomized Clinical Trial
INTERVENTIONAL
Inicio: 23 de may de 2025
ID: NCT07195058
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Multi-center Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adults and Compare to the Safety and Immune Response of a Licensed Conjugate Meningococcal ACWY Vaccine in Subjects Aged 19-55 Years of Age and to a Licensed Polysaccharide Vaccine in Subjects Aged 56-65 Years of Age.
INTERVENTIONAL
Inicio: 1 de may de 2007
ID: NCT00474487
Completado
Fase 3
ClinicalTrials.gov
A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS
INTERVENTIONAL
Inicio: 3 de dic de 2018
ID: NCT03732807
Completado
Fase 2
ClinicalTrials.gov
A Phase II, Open-label Trial, to Evaluate the Safety, Tolerability and Antiviral Activity of TMC125 in Antiretroviral Experienced HIV-1 Infected Children and Adolescents
INTERVENTIONAL
Inicio: 1 de nov de 2008
ID: NCT00665847
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Observer-Blind, Randomized, Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Immunogenicity of Two Trivalent Subunit Inactivated Influenza Vaccines in Healthy Children Aged 3 to 8 Years, in Healthy Children/Adolescents Aged 9 to 17 Years,and in Healthy Adults Aged 18 to 64 Years
INTERVENTIONAL
Inicio: 1 de abr de 2007
ID: NCT00464672
Completado
Fase 3
ClinicalTrials.gov
An Open Label, Single Arm Study to Assess the Safety and Immunogenicity of Omalizumab Liquid Administered Subcutaneously to Male and Female Adolescents and Adults With Persistent Allergic Asthma
INTERVENTIONAL
Inicio: 1 de jul de 2007
ID: NCT00500539
Completado
Fase 3
ClinicalTrials.gov
Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy
INTERVENTIONAL
Inicio: 28 de mar de 2014
ID: NCT02002884
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Double-dummy, Parallel-group Multicentre Study to Assess Efficacy and Safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents
INTERVENTIONAL
Inicio: 1 de jun de 2010
ID: NCT01147848
Activo, no recluta
Fase 4
ClinicalTrials.gov
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
INTERVENTIONAL
Inicio: 4 de nov de 2019
ID: NCT03975829
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
INTERVENTIONAL
Inicio: 8 de mar de 2012
ID: NCT01550003
Completado
ClinicalTrials.gov
Elaboration, Development and Validation of Predictive Models of Weight and Height for the Evaluation of the Growth of Children and Adolescents With Cerebral Palsy
OBSERVATIONAL
Inicio: 1 de abr de 2014
ID: NCT03303755
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection
INTERVENTIONAL
Inicio: 3 de ene de 2018
ID: NCT03376321
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Serious Influenza
INTERVENTIONAL
Inicio: 1 de nov de 2009
ID: NCT00958776
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 1 de oct de 2025
ID: NCT07196748
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III Multicenter, Randomized, Double-blind, Double-dummy Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
INTERVENTIONAL
Inicio: 19 de may de 2022
ID: NCT05123703
Reclutando
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis
INTERVENTIONAL
Inicio: 2 de oct de 2023
ID: NCT05609630
Anterior
1
...
16
17
18
...
434
Siguiente
Filtros